Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.
1. A method of making a drug nanocarrier, comprising:
providing a nanocarrier comprising a silica body having a surface including a plurality of pores suitable to receive molecules therein, disposing a cargo trapping agent within the plurality of pores;
coating the plurality of pores of the nanocarrier with a phospholipid bilayer, wherein the phospholipid bilayer encapsulates said silica body and seals the plurality of pores; and
introducing a cargo comprising a drug into the plurality of pores, so that a phospholipid bilayer coated drug nanocarrier is made, wherein the nanocarrier shows <5% drug leakage over 24 hours in a biological buffer with pH of 7.4 at 37° C.
2. The method of claim 1 , wherein said silica body comprises a sol-gel synthesized, size-controlled and colloidally stable silica body.
3. The method of claim 1 , wherein the cargo trapping agent is a protonating agent.
4. The method of claim 3 , wherein the protonating agent comprises an ammonium salt, a trimethylammonium salt, a triethylammonium salt, or an ionophore combined with a metal salt.
5. The method of claim 3 , wherein the protonating agent is triethylammonium sucrose octasulfate (TEA8SOS).
6. The method of claim 3 , wherein the nanocarrier has a drug loading capacity of at least 20% w/w.
7. The method of claim 6 , wherein the nanocarrier has colloidal stability in physiological fluids with pH 7.4 and remains monodisperse to allow systemic biodistribution and is capable of entering a disease site by vascular leakage or transcytosis.
8. The method of claim 1 , wherein the phospholipid bilayer comprises cholesterol.
9. A method of making a nanocarrier, comprising:
providing an unloaded nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein, and a phospholipid bilayer coating the surface; and
encapsulating a cargo-trapping agent within the phospholipid bilayer.
10. The method of claim 9 , further comprising exposing the nanocarrier to a cargo selected to interact with the cargo-trapping agent.
11. The method of claim 10 , wherein the cargo is selected to have a pKa greater than 7 and less than 11 and capable of being protonated, and the cargo-trapping agent includes at least one anionic group.
12. The method of claim 10 , wherein the cargo is irinotecan and the cargo-trapping agent is triethylammonium sucrose octasulfate (TEA8SOS).
13. The method of claim 10 , wherein the cargo is a topoisomerase I inhibitor, topotecan; one or more antitumor anthracycline antibiotics, doxorubicin and mitoxantrone; one or more mitotic inhibitors, vinblastine and vinorelbine; or one or more tyrosine-kinase inhibitors imatinib, osimertinib, and sunitinib.
14. The method of claim 10 , wherein the nanocarrier has a drug loading capacity of at least 30% w/w.
15. The method of claim 10 , wherein the cargo comprises one or more drugs independently selected from the group consisting of a topoisomerase inhibitor, an antitumor anthracycline antibiotic, a mitotic inhibitor, an alkaloid, an alkaline alkylating agent, a purine or pyrimidine derivative, and a protein kinase inhibitor.
16. The method of claim 10 , wherein the cargo-trapping agent converts the cargo into a hydrophilic derivative that is incapable of back diffusion across the lipid bilayer.
17. The method of claim 2 , wherein the cargo is protonated by the cargo-trapping agent and trapped in the plurality of pores as a gel precipitate.
18. The method of claim 10 , wherein the cargo-trapping agent before reaction with the cargo comprises an ammonium salt, a trimethylammonium salt, a triethylammonium salt, or an ionophore combined with a metal salt.
19. The method of claim 18 , wherein the ammonium salt is selected from the group consisting of ammonium sulfate, ammonium sucrose octasulfate, ammonium α-cyclodextrin sulfate, ammonium β-cyclodextrin sulfate, ammonium γ-cyclodextrin sulfate, ammonium phosphate, ammonium α-cyclodextrin phosphate, ammonium β-cyclodextrin phosphate, ammonium γ-cyclodextrin phosphate, ammonium citrate, and ammonium acetate.
20. The method of claim 18 , wherein the trimethylammonium salt is selected from the group consisting of trimethylammonium sulfate, trimethylammonium sucrose octasulfate, trimethylammonium α-cyclodextrin sulfate, trimethylammonium β-cyclodextrin sulfate, trimethylammonium γ-cyclodextrin sulfate, trimethylammonium phosphate, trimethylammonium α-cyclodextrin phosphate, trimethylammonium β-cyclodextrin phosphate, trimethylammonium γ-cyclodextrin phosphate, trimethylammonium citrate, and trimethylammonium acetate.
21. The method of claim 18 , wherein the triethylammonium salt is selected from the group consisting of triethylammonium sulfate, triethylammonium sucrose octasulfate, triethylammonium α-cyclodextrin sulfate, triethylammonium β-cyclodextrin sulfate, triethylammonium γ-cyclodextrin sulfate, triethylammonium phosphate, triethylammonium α-cyclodextrin phosphate, triethylammonium β-cyclodextrin phosphate, triethylammonium γ-cyclodextrin phosphate, triethylammonium citrate, and triethylammonium acetate.
22. The method of claim 9 , wherein the method produces a plurality of nanocarriers having a median diameter of less than one micron.